One Plus One Wealth Management LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

One Plus One Wealth Management LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 15.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,412 shares of the company’s stock after selling 1,000 shares during the period. One Plus One Wealth Management LLC’s holdings in Johnson & Johnson were worth $898,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Professional Advisory Services Inc. boosted its holdings in Johnson & Johnson by 3.3% in the first quarter. Professional Advisory Services Inc. now owns 19,016 shares of the company’s stock valued at $3,154,000 after purchasing an additional 600 shares during the last quarter. Kennebec Savings Bank boosted its holdings in Johnson & Johnson by 6.2% in the first quarter. Kennebec Savings Bank now owns 7,125 shares of the company’s stock valued at $1,182,000 after purchasing an additional 418 shares during the last quarter. Wynn Capital LLC boosted its holdings in Johnson & Johnson by 25.8% in the first quarter. Wynn Capital LLC now owns 15,907 shares of the company’s stock valued at $2,638,000 after purchasing an additional 3,260 shares during the last quarter. Griffith & Werner Inc. boosted its holdings in Johnson & Johnson by 9.0% in the first quarter. Griffith & Werner Inc. now owns 30,693 shares of the company’s stock valued at $5,090,000 after purchasing an additional 2,526 shares during the last quarter. Finally, ARS Wealth Advisors Group LLC boosted its holdings in Johnson & Johnson by 1.8% in the first quarter. ARS Wealth Advisors Group LLC now owns 119,023 shares of the company’s stock valued at $19,739,000 after purchasing an additional 2,111 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.9%

Shares of Johnson & Johnson stock opened at $155.02 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The business’s 50 day simple moving average is $153.59 and its 200-day simple moving average is $153.67. The stock has a market capitalization of $372.99 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on JNJ shares. Raymond James reduced their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.